Don’t Let Your Pharma Program Fall Behind – Optimize It Now
How do you know if your program needs to be optimized? Here are several questions to ask yourself:
-
- Does your program seem misaligned with the overall brand ecosystem?
- Does your program face consistent escalations?
- Is your sales force focused more on the HUB process and pull-through than selling?
- Does your program metrics data seem “off”?
- Do seemingly small process changes cause setbacks?
- Does your team seem busy but unproductive?
- Do your vendor contacts seem to be burned out?
- Are you hearing conflicting information from your vendor and HCPs about cycle time or specific services?
- Do you have low HCP and/or patient satisfaction ratings?
- Is your program staff consistently working overtime?
If you answered “yes” to one or more of the questions above, program optimization could make sense.
Every program has its story, just like a resolution. Optimizing is about moving forward to a new and better chapter. Archbow can assist with your program optimization strategy. We are highly experienced in designing proactive optimization approaches, identifying room for improvement, analyzing vendor performance, and modernizing technology in existing programs. Contact us today to get started.
For additional insights on this topic, you may also enjoy the following:
Archbow Consulting helps pharmaceutical and biotech companies in the USA and Europe design, build, and optimize product distribution and patient access strategies. Archbow was founded by industry veterans to meet a need in the marketplace for consulting options that offer diverse real-world experience, are able to leverage deep connections across the industry, and can also provide actionable strategic guidance. We invite you to learn more about our team, services, and clients’ success, and connect with us via email, LinkedIn or subscribing to this blog which you can do below.
Share in
Recent Posts
FDA Extends Compliance Deadline for Updated DSCSA Requirements
Understanding the revised timeline for compliance with specific updated DSCSA requirements
Are Direct-to-Patient Access Models the Future of Pharma?
Understanding the opportunity to sell directly to patients via a cash model
Key Takeaways from NASP 2024
The 2024 National Association of Specialty Pharmacy (NASP) conference showcased a landscape of rapid innovation and evolving industry trends.
SUBSCRIBE
Subscribe to receive news and updates from Archbow Consulting
|